2022-11-02 . Financial Statements. You may all disconnect your lines at this time. An estimated 40 million people in the US, including approximately 10% of US children, are afflicted by this disease. 80% employee turnover ratio / year. The P/E ratio of Axcella Health is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. It is unlikely that we would continue with the six-minute walk as feedback we have gotten indicates that it is not reflective of the patient experience. 3rd Floor, Cambridge, Enrollment is continuing well, and we are obviously encouraged by the results that we saw across liver stiffness, inflammation, and metabolism, and continuing to show first line safety profile, as are the investigators. All rights reserved. In some, these findings indicate that administration of AXA1124 - excuse me, 25, over 24 weeks, leads to statistically significant improvements compared to placebo and biomarkers for metabolism, inflammation, and fibrosis. At 24 weeks, there was statistically significant improvements in the liver stiffness measurement, or LSM, compared to placebo for the subjects in the high-dose arm. Contact Email info@axcellahealth.com Phone Number 617-441-6243 Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. Axcella had nearly doubled off its January 24, 2022 all-time low of $1.44 after the company secured operating capital while approaching midyear catalysts. In terms of the approach, we're well positioned to execute the next trial in terms of our capabilities and our ongoing support. We'll have Margaret, our CMO, answer that question. Instead, our . What are your thoughts on the main reasons behind that, and if you still believe there's a opportunity in the Type 2 diabetes subpopulation in the NASH space for 1125? Axcella Health stock opened at $1.62 on Tuesday. Axcella Health stock opened at $1.46 on Friday. And across both indications, the overall safety and tolerability profile of 1125 is also best in the market. View analysts price targets for AXLA or view top-rated stocks among Wall Street analysts. All compounds discussed in this section are investigational in the US. Bob? Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis Compare AXLA With Other Stocks From: To: Zoom: 48 50 52 54 56 58 60 62 64 Number of Employees We believe that the diverse expertise and experiences of Axcellans enriches our way of thinking and is essential to achieving our goals. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. These filings can be accessed on our website, axcellatx.com, or on the SEC website. In addition, we intend to carry forward an assessment of physical function. Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Mar 28, 2022 But whatever you call it, the recent spate of layoffs in biotech is a voucher from Medicines Development for Global Health in 2019. https://www.yahoo.com/lifestyle/axcella-health-inc-axla-moves-160004592.html, Jun 24, 2020 Axcella Health Inc. (AXLA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the companys earnings , Fundamental Biology, Foundational BreakthroughsTM, https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2022, As the longtime chief exeuctive at the worlds largest healthcare Generate Biomedicines, Axcella Health and Sana Biotechnology, the last of which made , https://biopharmguy.com/links/company-by-name-defunct.php. Identify stocks that meet your criteria using seven unique stock screeners. Thank you so much and congrats on the progress. Is this happening to you frequently? No direction. Healthcare is dynamic and is inclusive of mind, body, and spirit. We encourage our employees to openly share their learnings throughout the organization, so we can actively incorporate these insights into our work. Good morning. Stock update. When NASH worsens, it can cause scarring of the liver, which leads to cirrhosis, and NASH is one of the most common causes of end-stage liver disease worldwide. View contact profiles from Axcella SIC Code 28,283 With over 15,000 employees globally, we partner with clients to operate as part of their extended team in ways that best suit their . Long-term financial health is important to all Axcellans, which is why we offer a 401k plan that matches 50% up to the first 6% of our employee's contribution in addition to Life Insurance. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. A downtrend has been apparent in Axcella Health Inc. (AXLA) lately. We'll update you appropriately. Got it. Axcella Health Inc. This amount included $6 million received as the cancellation of indebtedness upon the conversion of promissory notes held by Flagship Pioneering. We are focused on optimizing the experience. 3 days ago. Receive a free world-class investing education from MarketBeat. First question, can you discuss current thoughts on primary endpoint for long COVID Phase 3 study or registrational study, whether it includes any endpoints from the Phase 2a specifically the fatigue question here or the six-minute walk test? At Axcella, wellness is important to us. Axcella Health Inc's PE and . We foster an inclusive culture, actively seeking diverse perspectives. Amount of Analyst Coverage Axcella Health has only been the subject of 3 research reports in the past 90 days. Ticker Symbol AXLA. Thank you very much, sir. We are a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. View our AXLA earnings forecast. Long COVID is a persistent and growing challenge of the pandemic, affecting an estimated 100 million patients worldwide, with fatigue as the most common symptom reported. Want to see which stocks are moving? E: info@axcellatx.com. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. Axcella is pioneering transformative medicines for patients of diseases, where amino acid imbalances play a critical role. Helpful. (AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The CEO is very down to earth and quality-minded. This suggests a possible upside of 596.0% from the stock's current price. Now, finally, there was a statistically significant correlation between improvement in fatigue score and increase in distance achieved in the six-minute walk time with a P value of 0.0027. . What is Bill Hinshaw's approval rating as Axcella Health's CEO? We provide healthy snacks to keep our employees nourished, and adjustable desks and balance boards to keep our employees fit and well centered. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Should Investors Raise a Glass to Boston Beer Company? But in general, we're in a very good position to move our endpoints forward into Phase 3. Please be advised that todays call is being recorded, and that all participants will be in a listen-only mode until the question-and-answer session. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. Axcella Health number of employees from 2018 to 2022. Now, on August 2, we announced positive topline results from our Phase 2a study of AXA1125 in long COVID. This begins by genuinely caring about our employees and one another. We had projected enrollment closure in 23, and that's where we still plan to be. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. Our net loss for the third quarter and nine months ended September 30, 2021 was $15.6 million or $0.41 per share, and $46.7 million or $1.23 per share. Looking for new stock ideas? Axcella corporate office is located in 840 Memorial Dr Fl 3, Cambridge, Massachusetts, 02139, United States and has 97 employees. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Axcella Health Inc. (NASDAQ:AXLA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET, Good morning, ladies and gentlemen, and welcome to Axcellas third quarter 2022 conference call. Thank you very much for taking the questions. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being . Compare Top Brokerages Here. StockTwits Thank you very much. our clinical development of AXA1125, and strengthened our balance sheet with a new financing. Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. This past quarter, we completed a new round of financing, about which Bob Crane, our CFO, will provide details shortly. Axcella Health has received a consensus rating of Buy. The position requires strong collaboration with leaders, managers, employees, and the Head of HR. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. So, as you note, the size here is quite significant. The financing occurred at a market price of $1.64, and the company sold 20,847,888 shares of common stock to a combination of current investors, new investors, company directors, and management. Axcella Health benefits and perks, including insurance benefits, retirement benefits, and vacation policy. founded by flagship pioneering in 2009, axcella is a biotechnology company pioneering a new way to harness the power of endogenous metabolic modulators, or emms, with the goals of reprogramming metabolism and restoring metabolic health to treat a broad range of complex diseases and health conditions in ways that are simply not possible with 'Stay alive': Wave of layoffs crashes into biotech startup inferno https://www.fiercebiotech.com/biotech/just-beginning-layoff-wave-rise-after-30-plus-biopharmas-slashed-jobs-past-six-months About; Work. Revenue. According to analysts' consensus price target of $6.25, Axcella Health has a forecasted upside of 596.0% from its current price of $0.90. Full Company Profile. O: 857-320-2200 F: 617-441-6243 E: info@axcellatx.com Footer. Were looking forward to our upcoming milestones and progress that we'll make across the programs, and we expect to help drive value for our shareholders. Long-term financial health is important to all Axcellans, which is why we offer a 401k plan that matches 50% up to the first 6% of our employees contribution in addition to Life Insurance. So, we're consistent with that. Please go ahead, sir. HC Wainwright increased their price objective on Axcella Health from $8.00 to $10.00 and gave the stock a buy rating in a report on Monday, October 3rd. Got it. Their AXLA share price forecasts range from $5.00 to $8.00. 77.0% of employees surveyed would recommend working at Axcella Health to a friend. Our net. Axcella Health's stock was trading at $2.09 on January 1st, 2022. [Operator Instructions]. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. So, Thomas, thank you. Export data to Excel for your own analysis. This concludes the review of our finances. These risks and uncertainties are detailed in our SEC filings, including our most recent Form 10-Q, which we plan to file later today. Again, this is a validated instrument, a patient reported outcome that is - and such measures are well accepted by the FDA and other health authorities. Since then, AXLA shares have decreased by 57.0% and is now trading at $0.8980. Indeed, Time Magazine has described long COVID as the greatest mass disabling event in history. The stock is currently down 10.0% year-to-date, down 63.9% over the past 12 months, and down 86.4% over the past five years. Get daily stock ideas from top-performing Wall Street analysts. Please log in to your account or sign up in order to add this asset to your watchlist. Societe des Produits Nestle S.A. bought 3,658,536 shares of AXLA stock at an average price of $1.64 per share, worth $6 million. Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC Please. F: 617-441-6243 So, what's your strategy to alleviate the financing overhang in 2023? Earnings for Axcella Health are expected to grow in the coming year, from ($1.39) to ($1.05) per share. We are certainly energized by the opportunity to help address the substantial needs of patients who have long COVID fatigue and NASH. Time Off Axcellas net loss for the quarter and nine months ended September 30, 2022, was $17.8 million, or $0.34 per basic and diluted share, and $58.2 million or $1.19 per share, respectively. Share your opinion and gain insight from other stock traders and investors. These results were supported by statistically significant improvements in other non-invasive measures of liver fibrosis, ELF, and FIB four. 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last twelve months. All; PR&Campaign; ATL; BTL; Media. Sign in to your free account to enjoy all that MarketBeat has to offer. The company entered into a securities purchase agreement with investors to offer 20,847,888 shares of common stock at a purchase price of $1.64 per share. Axcella Health does not currently pay a dividend. Print. For Axcella Health profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Axcella Health to generate income relative to revenue, assets, operating costs, and current equity. Absolute changes in LSM were 0.13 minus 2.01 for P value of 0.0992, compared to placebo, and minus 4.07 kilo pascals or KPA for a P value of 0.0096 compared to placebo in the placebo low and high-dose arms. The firm has a market capitalization of $76.85 million, a P/E ratio of -0.84 and a beta of 1.23. We would like to advise that certain remarks we will make on todays conference call, such as those relating to our cash runway and our ongoing clinical trials of AXA1125, include forward-looking statements that are subject to various risks and uncertainties. Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter. . The Companys product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting .